Saudi clinical practice guidelines for the treatment and prevention of migraine headache

References

1. 1.↵
   1. Stovner LJ,
   2. Hagen K,
   3. Linde M,
   4. Steiner TJ.

   The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 2022; 23: 1-17.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Albalawi MF,
   2. Alanazi WL,
   3. Albalawi HS,
   4. Alghannami SS,
   5. Albalawi AF.

   Prevalence of Migraine Headache in Saudi Arabia: A Systematic Review and Meta-Analysis. Cureus 2023; 15: e37560.

   OpenUrl
3. 3.↵
   1. Burch R,
   2. Rizzoli P,
   3. Loder E.

   The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache J Head Face Pain 2021; 61: 60-68.

   OpenUrl
4. 4.↵
   1. Cohen F,
   2. Brooks C V,
   3. Sun D,
   4. Buse DC,
   5. Reed ML,
   6. Fanning KM, et al.

   Prevalence and burden of migraine in the United States: A systematic review. Headache J Head Face Pain 2024; 64: 516-532.

   OpenUrl
5. 5.↵
   1. Al Jumah M,
   2. Al Khathaami AM,
   3. Kojan S,
   4. Husøy A,
   5. Steiner TJ.

   The burden of headache disorders in the adult general population of the Kingdom of Saudi Arabia: estimates from a cross-sectional population-based study including a health-care needs assessment. J Headache Pain 2024; 25: 66.

   OpenUrlPubMed
6. 6.↵
   1. Dai W,
   2. Liu RH,
   3. Qiu E,
   4. Liu Y,
   5. Chen Z,
   6. Chen X, et al.

   Cortical mechanisms in migraine. Mol Pain 2021; 17: 174480692110502.

   OpenUrl
7. 7.↵
   1. AlHarbi F,
   2. AlAteeq M.

   Quality of life of migraine patients followed in neurology clinics in Riyadh, Saudi Arabia. J Fam Community Med 2020; 27: 37.

   OpenUrl
8. 8.↵
   1. Lipton RB,
   2. Dodick DW,
   3. Goadsby PJ,
   4. Burstein R,
   5. Adams AM,
   6. Lai J, et al.

   Efficacy of ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain. Neurology 2022; 99: e1905–e1915.

   OpenUrlPubMed
9. 9.↵
   1. Burch R.

   Preventive Migraine Treatment. Contin Lifelong Learn Neurol 2021; 27: 613-632.

   OpenUrl
10. 10.↵
    1. Hien Ha,
    2. Gonzalez A.

    Migraine Headache Prophylaxis. Am Fam Physician 2019; 99: 17-24.

    OpenUrlPubMed
11. 11.↵
    1. Alhazzani A,
    2. Alotaibi N,
    3. Kojan S,
    4. Murad M,
    5. Obaid M,
    6. Riva J, et al.

    Clinical practice guideline on migraine headache diagnosis and management: Kingdom of Saudi Arabia EBHC 2016; https://www.researchgate.net/publication/294425019_Clinical_Practice_Guideline_on_Migraine_Headache_Diagnosis_Management_Kingdom_of_Saudi_Arabia_EBHC
12. 12.↵
    1. Kirmayr M,
    2. Quilodrán C,
    3. Valente B,
    4. Loezar C,
    5. Garegnani L,
    6. Franco JVA.

    The GRADE approach, Part 1: how to assess the certainty of the evidence. Medwave 2021; 21:e8109.

    OpenUrl
13. 13.↵
    Network Scottish Intercollegiate Guidelines. Migarine; A booklet for people with migraine, their families and carers. 2023; From URL: https://www.sign.ac.uk/media/2065/pat-155-migraine-2023-update-0-2.pdf
14. 14.↵
    GRADEpro GDT tool. From URL: https://www.gradepro.org/
15. 15.↵
    1. Higgins JPT,
    2. Altman DG,
    3. Gotzsche PC,
    4. Juni P,
    5. Moher D,
    6. Oxman AD, et al.

    The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928–d5928.

    OpenUrlFREE Full Text
16. 16.↵
    “GRADE handbook.” No Title. From URL: https://gdt.gradepro.org/app/handbook/handbook.html
17. 17.↵
    1. VanderPluym JH,
    2. Halker Singh RB,
    3. Urtecho M,
    4. Morrow AS,
    5. Nayfeh T,
    6. Torres Roldan VD, et al.

    Acute Treatments for Episodic Migraine in Adults. JAMA 2021; 325: 2357.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Derry S,
    2. Moore RA.

    Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013; 2013: CD008040.
19. 19.↵
    1. Rabbie R,
    2. Derry S,
    3. Moore RA.

    Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013; 2013: CD008039.
20. 20.↵
    1. Suthisisang C,
    2. Poolsup N,
    3. Kittikulsuth W,
    4. Pudchakan P,
    5. Wiwatpanich P.

    Efficacy of Low-Dose Ibuprofen in Acute Migraine Treatment: Systematic Review and Meta-Analysis. Ann Pharmacother 2007; 41: 1782-1791.

    OpenUrlCrossRefPubMed
21. 21.↵
    62 nd Annual Scientific Meeting American Headache Society®. Headache J Head Face Pain 2020; 60: 1-156.

    OpenUrl
22. 22.↵
    1. Tepper S,
    2. Serrano D,
    3. Ko M,
    4. Lipton R,
    5. Kunkel T.

    Efficacy of Celecoxib Oral Solution in Adults With and Without Baseline Nausea: Post Hoc Analysis of Results From Two Randomized, Double-Blind Placebo-Controlled Trials in the Acute Treatment of Migraine (P14-12.009). Neurology 2023; 100: 14.

    OpenUrl
23. 23.↵
    1. Lipton RB,
    2. Munjal S,
    3. Dodick DW,
    4. Tepper SJ,
    5. Serrano D,
    6. Iaconangelo C.

    Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. J Pain Res 2021; 14: 549-560.

    OpenUrlPubMed
24. 24.↵
    1. Ailani J,
    2. Nahas SJ,
    3. Friedman DI,
    4. Kunkel T.

    The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review. Pain Ther 2023; 12: 655-669.

    OpenUrlPubMed
25. 25.↵
    1. Yang CP,
    2. Liang CS,
    3. Chang CM,
    4. Yang CC,
    5. Shih PH,
    6. Yau YC, et al.

    Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine. JAMA Netw Open 2021; 4: e2128544.

    OpenUrl
26. 26.↵
    1. Derry CJ,
    2. Derry S,
    3. Moore RA.

    Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 2012: CD008615.
27. 27.↵
    1. Derry CJ,
    2. Derry S,
    3. Moore RA.

    Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 2014: CD009108.
28. 28.↵
    1. Zaazouee MS,
    2. Abdel-Aziz W,
    3. Elassall GM,
    4. Mohammed YA,
    5. Gbreel MI,
    6. Attia AM, et al.

    Efficacy and Safety of Subcutaneous Sumatriptan for Acute Migraine Attacks Compared with other treatments: A Systematic Review and Network Meta-analysis.(P12-2.005). Neurology 2022; 98: 1156.

    OpenUrl
29. 29.↵
    1. Brown EG,
    2. Endersby CA,
    3. Smith RN,
    4. Talbot JC.

    The Safety and Tolerability of Sumatriptan: An Overview. Eur Neurol 1991; 31: 339-344.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Friedman BW,
    2. Solorzano C,
    3. Esses D,
    4. Xia S,
    5. Hochberg M,
    6. Dua N, et al.

    Treating Headache Recurrence After Emergency Department Discharge: A Randomized Controlled Trial of Naproxen Versus Sumatriptan. Ann Emerg Med 2010; 56: 7-17.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Belvis R,
    2. Pagonabarraga J,
    3. Kulisevsky J.

    Individual Triptan Selection in Migraine Attack Therapy. Recent Pat CNS Drug Discov 2009; 4: 70-81.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Maitland S,
    2. Baker M.

    Serotonin syndrome. Drug Ther Bull 2022; 60: 88-91.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Abdelmonem H,
    2. Abdelhay HM,
    3. Abdelwadoud GT,
    4. Alhosini ANM,
    5. Ahmed AE,
    6. Mohamed SW, et al.

    The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. BMC Neurol 2023; 23: 1-30.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Funato Y,
    2. Kimura A,
    3. Matsuda W,
    4. Uemura T,
    5. Kobayashi K,
    6. Sasaki R.

    Pain relief effect of metoclopramide vs. sumatriptan for acute migraine attack: A single-center, open-label, cluster-randomized controlled non-inferiority trial. GHM Open 2024; 4: 95-98.

    OpenUrlPubMed
35. 35.↵
    1. Doğan NÖ,
    2. Pekdemir M,
    3. Yılmaz S,
    4. Yaka E,
    5. Karadaş A,
    6. Durmuş U, et al.

    Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial. Acta Neurol Scand 2019; 139: 334–339.

    OpenUrlPubMed
36. 36.↵
    1. Khazaei M,
    2. Hosseini Nejad Mir N,
    3. Yadranji Aghdam F,
    4. Taheri M,
    5. Ghafouri-Fard S.

    Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial. Neurol Sci 2019; 40: 1029-1033.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. Ungrungseesopon N,
    2. Wongtanasarasin W.

    Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials. World J Methodol 2022; 12: 319-330.

    OpenUrlPubMed
38. 38.↵
    1. Schwedt TJ,
    2. Garza I.

    Acute treatment of migraine in adults. In: UpToDate [Internet]. Waltham (MA): UpToDate Inc.; 2025 Feb 19 [cited 2025 Mar 12]. Available from: https://www.uptodate.com/contents/acute-treatment-of-migraine-in-adults
39. 39.↵
    1. Norteman K,
    2. Awosika AO. Eletriptan

    . Treasure Island (FL): StatPearls Publishing; 2025.
40. 40.↵
    1. Singh O,
    2. Sharma S,
    3. Naagar M,
    4. Maity MK.

    Eletriptan As Treatment Option For Acute Migraine. Int J Innov Res Anal 2022; 2: 15–24.

    OpenUrl
41. 41.↵
    1. Yang C,
    2. Zhang Y.

    Efficacy and Safety of Rimegepant for Migraine Patients: A Meta-analysis of Randomized Controlled Studies. Clin Neuropharmacol 2024; 47: 7-11.

    OpenUrlPubMed
42. 42.↵
    1. Puledda F,
    2. Younis S,
    3. Huessler EM,
    4. Haghdoost F,
    5. Lisicki M,
    6. Goadsby PJ, et al.

    Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia 2023; 43: 1-13.

    OpenUrl
43. 43.↵
    1. Lipton RB,
    2. Dodick DW,
    3. Ailani J,
    4. Lu K,
    5. Finnegan M,
    6. Szegedi A, et al.

    Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine. JAMA 2019; 322: 1887.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Cameron C,
    2. Kelly S,
    3. Hsieh S,
    4. Murphy M,
    5. Chen L,
    6. Kotb A, et al.

    Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache 2015; 55: 221-235.

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Thorlund K,
    2. Mills EJ,
    3. Wu P,
    4. Ramos E,
    5. Chatterjee A,
    6. Druyts E, et al.

    Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 2014; 34: 258-267.

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    1. Almas M,
    2. Tepper SJ,
    3. Landy S,
    4. Schweizer E,
    5. Ramos E.

    Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. Cephalalgia 2014; 34: 126-135.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Hasan Abdi S,
    2. Sayed S,
    3. Bhaskar J.

    Serotonin receptor agonist and risk of paresthesia in migraine patients: A dose-response model-based (network) meta-analysis. Ann Indian Acad Neurol 2022; 25: 669.

    OpenUrlPubMed
48. 48.↵
    1. Merino D,
    2. Gérard AO,
    3. Van Obberghen EK,
    4. Destere A,
    5. Lanteri-Minet M,
    6. Drici MD.

    The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans. Neurotherapeutics 2023; 20: 1305-1315.

    OpenUrlPubMed
49. 49.↵
    1. Maiti R,
    2. Mishra A,
    3. Puliappadamb HM,
    4. Jena M,
    5. Srinivasan A.

    Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis. J Clin Pharmacol 2021; 61: 1534-1544.

    OpenUrlPubMed
50. 50.↵
    1. Yang Y,
    2. Sun Y,
    3. Gao B,
    4. Wang Z,
    5. Chen Z,
    6. Wang Z.

    Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs 2020; 34: 1015–1024.

    OpenUrlPubMed
51. 51.↵
    1. Zhu H,
    2. Tang Y,
    3. Zhou T,
    4. Song J.

    The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies. Clin Neuropharmacol 2020; 43: 191-195.

    OpenUrlPubMed
52. 52.↵
    U. S. FOOD & DRUG. Drug Trials Snapshots: REYVOW. From URL: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-reyvow
53. 53.↵
    1. Dogruyol S,
    2. Gur STA,
    3. Akbas I,
    4. Kocak MB,
    5. Kocak AO,
    6. Ceylan M, et al.

    Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: A randomized clinical trial. Am J Emerg Med 2022; 55: 126-132.

    OpenUrlPubMed
54. 54.↵
    1. Wang F,
    2. Zhang H,
    3. Wang L,
    4. Cao Y,
    5. He Q.

    Intravenous sodium valproate for acute migraine in the emergency department: A meta-analysis. Acta Neurol Scand 2020; 142: 521-530.

    OpenUrlPubMed
55. 55.↵
    1. Mazaheri S,
    2. Poorolajal J,
    3. Hosseinzadeh A,
    4. Fazlian MM.

    Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial. PLoS One 2015; 10: e0120229.

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Cui XY,
    2. Sun SM,
    3. Liu J,
    4. Wu QY,
    5. Zhang JF,
    6. Li X.

    The efficacy and safety of valproate medications for migraine in adults: A meta-analysis. Eur Rev Med Pharmacol Sci 2020; 24: 5734-5741.

    OpenUrlCrossRefPubMed
57. 57.
    1. Jackson JL,
    2. Kuriyama A,
    3. Kuwatsuka Y,
    4. Nickoloff S,
    5. Storch D,
    6. Jackson W, et al.

    Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14: e0212785.

    OpenUrlPubMed
58. 58.
    1. He A,
    2. Song D,
    3. Zhang L,
    4. Li C.

    Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain 2017; 18.
59. 59.
    1. Yiannakis C,
    2. Hamilton L,
    3. Slim M,
    4. Kontorinis G.

    A systematic review and meta-analysis of prophylactic medication of vestibular migraine. J Laryngol Otol 2023; 137: 953-961.

    OpenUrlPubMed
60. 60.
    1. Lampl C,
    2. MaassenVanDenBrink A,
    3. Deligianni CI,
    4. Gil-Gouveia R,
    5. Jassal T,
    6. Sanchez-del-Rio M, et al.

    The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 2023; 24: 1-14.

    OpenUrlCrossRefPubMed
61. 61.
    1. Raffaelli B,
    2. García-Azorín D,
    3. Boucherie DM,
    4. Amin FM,
    5. Deligianni CI,
    6. Gil-Gouveia R, et al.

    European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate. J Headache Pain 2023; 24: 1-13.

    OpenUrlCrossRefPubMed
62. 62.
    1. Frank F,
    2. Ulmer H,
    3. Sidoroff V,
    4. Broessner G.

    CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia 2021; 41: 1222-1239.

    OpenUrlPubMed
63. 63.
    1. Zhang Y,
    2. Deng Y,
    3. Zhang S,
    4. Du X,
    5. Ji Y.

    Systematic review and meta-analysis of a variety of chemicals to treat migraine in the neurology department. Ann Palliat Med 2022; 11: 98-112.

    OpenUrlPubMed
64. 64.
    1. Linde M,
    2. Mulleners WM,
    3. Chronicle EP,
    4. Mccrory DC.

    Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; 2013: CD010611.
65. 65.
    1. Mohammadianinejad SE,
    2. Rafie S,
    3. Farashi S.

    A comparative study on the effectiveness of topiramate and propranolol in patients with migraine with aura. Curr J Neurol 2022; 21: 7-11.

    OpenUrlPubMed
66. 66.
    1. Jackson JL,
    2. Cogbill E,
    3. Santana-Davila R,
    4. Eldredge C,
    5. Collier W,
    6. Gradall A, et al.

    A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS One 2015; 10: e0130733.

    OpenUrlCrossRefPubMed
67. 67.
    1. Chowdhury D,
    2. Bansal L,
    3. Duggal A,
    4. Datta D,
    5. Mundra A,
    6. Krishnan A, et al.

    TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 2022; 42: 396-408.

    OpenUrlPubMed
68. 68.
    1. Patel KM,
    2. Popatbhai KM,
    3. Xavier R,
    4. Aramin MAS,
    5. Faris KJF,
    6. Mateen MA, et al.

    Comparison of the efficacy of propranolol versus amitriptyline as monotherapy for prophylaxis of migraine. J Fam Med Prim Care 2024; 13: 699-703.

    OpenUrl
69. 69.
    1. Tonekaboni SH,
    2. Ghazavi A,
    3. Fayyazi A,
    4. Khajeh A,
    5. Taghdiri MM,
    6. Abdollah Gorji F, et al.

    Prophylaxis of childhood migraine: topiramate versus propranolol. Iran J child Neurol 2013; 7: 9-14.

    OpenUrlPubMed
70. 70.
    1. Diener HC,
    2. Tfelt-Hansen P,
    3. Dahlof C,
    4. Lainez MJA,
    5. Sandrini G,
    6. Wang SJ, et al.

    Topiramate in migraine prophylaxis. J Neurol 2004; 251: 943-950.

    OpenUrlPubMedWeb of Science
71. 71.
    1. Huang T,
    2. Xu Y,
    3. Chen Y,
    4. Bian J,
    5. Chu Z,
    6. Zhao S, et al.

    Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: A meta-analysis. Brain Behav 2022; 12: e2542.

    OpenUrlPubMed
72. 72.
    1. Yang CP,
    2. Zeng BY,
    3. Chang CM,
    4. Shih PH,
    5. Yang CC,
    6. Tseng PT, et al.

    Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials. Neurotherapeutics 2021; 18: 2639-2650.

    OpenUrlPubMed
73. 73.
    1. Hou M,
    2. Xing H,
    3. Cai Y,
    4. Li B,
    5. Wang X,
    6. Li P, et al.

    The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 2017; 18: 1-12.

    OpenUrlPubMed
74. 74.
    1. Deng H,
    2. Li Gai-Gai,
    3. Nie H,
    4. Feng Yang-Yang,
    5. Guo Guang-Yu,
    6. Guo Wen-Liang, et al.

    Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis. BMC Neurol. 2020; 20: 57.

    OpenUrlPubMed
75. 75.
    1. Muddam MR,
    2. Obajeun OA,
    3. Abaza A,
    4. Jaramillo AP,
    5. Sid Idris F,
    6. Anis Shaikh H, et al.

    Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review. Cureus 2023; 15: e45560.

    OpenUrlPubMed
76. 76.
    1. Zhao X,
    2. Xu X,
    3. Li Q.

    Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis. J Neurol 2021; 268: 2364-2376.

    OpenUrlPubMed
77. 77.
    1. Naghdi S,
    2. Underwood M,
    3. Madan J,
    4. Brown A,
    5. Duncan C,
    6. Matharu M, et al.

    Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. J Headache Pain 2023; 24: 1–10.

    OpenUrlCrossRefPubMed
78. 78.
    1. Siahaan YMT,
    2. Hartoyo V,
    3. Hariyanto TI.

    Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol 2022; 49: 1156-1168.

    OpenUrlPubMed
79. 79.
    1. Yan Z,
    2. Xue T,
    3. Chen S,
    4. Wu X,
    5. Yang X,
    6. Liu G, et al.

    Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials. J Headache Pain 2021; 22: 1-12.

    OpenUrlPubMed
80. 80.
    1. Smith TR,
    2. Spierings ELH,
    3. Cady R,
    4. Hirman J,
    5. Schaeffler B,
    6. Shen V, et al.

    Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 2021; 22: 16.

    OpenUrlPubMed
81. 81.
    1. Lanteri-Minet M,
    2. Ducros A,
    3. Francois C,
    4. Olewinska E,
    5. Nikodem M,
    6. Dupont-Benjamin L.

    Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. Cephalalgia 2022; 42: 1543-1564.

    OpenUrlPubMed
82. 82.
    1. Giri S,
    2. Tronvik E,
    3. Linde M,
    4. Pedersen SA,
    5. Hagen K.

    Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia 2023; 43: 3331024231156922.

    OpenUrlPubMed
83. 83.
    1. Herd CP,
    2. Tomlinson CL,
    3. Rick C,
    4. Scotton WJ,
    5. Edwards J,
    6. Ives NJ, et al.

    Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open 2019; 9: 1-8.

    OpenUrlAbstract/FREE Full Text
84. 84.
    1. Velásquez-Rimachi V,
    2. Chachaima-Mar J,
    3. Cárdenas-Baltazar EC,
    4. Loayza-Vidalon A,
    5. Cristian Morán-Mariños C,
    6. Pacheco-Barrios K, et al.

    Greater occipital nerve block for chronic migraine patients: A meta-analysis. Acta Neurol Scand 2022; 146: 101-114.

    OpenUrlPubMed
85. 85.
    1. Tang Y,
    2. Kang J,
    3. Zhang Y,
    4. Zhang X.

    Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis. Am J Emerg Med 2017; 35: 1750-1754.

    OpenUrlCrossRefPubMed
86. 86.
    1. Tao X,
    2. Yan Z,
    3. Meng J,
    4. Wang W,
    5. Dai Q,
    6. Zhou Q, et al.

    The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain 2022; 23: 19.

    OpenUrlPubMed
87. 87.
    1. Messina R,
    2. Huessler EM,
    3. Puledda F,
    4. Haghdoost F,
    5. Lebedeva ER,
    6. Diener HC.

    Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia 2023; 43.
88. 88.
    1. Lampl C,
    2. Versijpt J,
    3. Amin FM,
    4. Deligianni CI,
    5. Gil-Gouveia R,
    6. Jassal T, et al.

    European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline. J Headache Pain 2023; 24: 1-12.

    OpenUrlCrossRefPubMed
89. 89.
    1. Hu C,
    2. Fan Y,
    3. Wu S,
    4. Zou Y,
    5. Qu X.

    Vitamin D supplementation for the treatment of migraine: A meta-analysis of randomized controlled studies. Am J Emerg Med 2021; 50: 784-788.

    OpenUrlPubMed
90. 90.
    1. Zhang Yuan-Feng,
    2. Xu Zhi-Qiang,
    3. Zhou Hong-Jie,
    4. Liu Ya-Zhen,
    5. Jiang Xiao-Jiang

    . The Efficacy of Vitamin D Supplementation for Migraine: A Meta-Analysis of Randomized Controlled Studies. Clin Neuropharmacol. 2021; 44: 5-8.

    OpenUrlPubMed
91. 91.
    1. Ghorbani Z,
    2. Rafiee P,
    3. Fotouhi A,
    4. Haghighi S,
    5. Rasekh Magham R,
    6. Ahmadi ZS, et al.

    The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. J Headache Pain 2020; 21: 22.

    OpenUrlPubMed